{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-134322","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2022-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.617720+00:00","generated_at":"2026-06-26T02:32:44.509063+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CFO Richard J. Wanstall resigns effective May 6, 2022 for other opportunity","bullets":["Richard J. Wanstall, CFO and principal accounting officer, resigns effective May 6, 2022 to pursue another career opportunity.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Aileron has initiated a search for a new CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-134322","json":"https://secwatch.observer/filing/0001193125-22-134322.json","markdown":"https://secwatch.observer/filing/0001193125-22-134322.md","text":"https://secwatch.observer/filing/0001193125-22-134322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522134322/0001193125-22-134322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522134322/d266198d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:32:44.509063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"511653e078","claim":"Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522134322/0001193125-22-134322-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}